[ay-LEN-droh-nayt] Pregnancy Category: C Fosamax [Rx]
Classification: Bone growth regulator (biphosphonate)
D Action/Kinetics: Alendronate inhibits osteoclast activity, thereby preventing bone resorption. It appears to reduce fracture risk and reverse the progression of osteoporosis. Alendronate does not inhibit bone mineralization. It is well absorbed orally and is initially distributed to soft tissues, but then quickly redistributed to bone. The drug is not metabolized and is excreted through the urine. However, the tV2, terminal is believed to be more than 10 years, due to slow release from the skeleton. Uses: Prevention and treatment of osteoporosis in postmenopausal women (concomitant estrogen therapy is not recommended due to lack of experience). Prevention of fractures in postmenopausal women with osteoporosis. Paget's disease of bone. Contraindications: In hypocalce-mia. Those with severe renal insufficiency (creatinine clearance less than 35 mL/min). Lactation. Special Concerns: Use with caution in those with upper GI problems, such as dysphagia, symptomatic esophageal diseases, gastritis, duodenitis, or ulcers. Safety and effectiveness have not been determined in children or for use in male osteoporosis.
Side Effects: Oral: Taster perversion. GI: Abdominal pain, nausea, dyspepsia, constipation, diarrhea, flatulence, acid regurgitation, esoph-ageal ulcer, vomiting, dysphagia, abdominal distention, gastritis. Miscellaneous: Musculoskeletal pain, headache, rash and erythema (rare). Drug Interactions Antacids / l Absorption of alendro-nate
Aspirin / T Risk of upper GI events Calcium supplements / l Absorption of alendronate NSAIDs / T Risk of upper GI events Ranitidine / T Bioavailability of alendronate (significance not known)
How Supplied: Tablet: 10 mg, 40 mg
Was this article helpful?